Condition:   Breast Cancer
Intervention:  
Sponsors:   Genentech;   Genentech;   23andMe, Inc.
Recruiting - verified May 2012

Condition:   Colorectal Cancer
Intervention:  
Sponsors:   Epigenomics, Inc;   Epigenomics, Inc
Recruiting - verified April 2012

Condition:   Glioblastoma
Interventions:   Drug: LY2157299 monohydrate;   Drug: Lomustine;   Drug: Placebo
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Brain Tumor
Intervention:   Drug: Sulfasalazine
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Recruiting - verified April 2012

Conditions:   Brain and Central Nervous System Tumors;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: trebananib;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: GS-1101 + Rituximab;   Drug: Placebo + Rituximab
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified April 2012

Conditions:   Advanced NET of GI Origin;   Advanced NET of Lung Origin;   Neuroendocrine Tumors
Interventions:   Drug: Everolimus;   Drug: Everolimus Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component;   Recurrent Glioblastoma;   Relapsed Glioblastoma
Interventions:   Drug: Bevacizumab;   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: KLH
Sponsors:   Celldex Therapeutics;   Celldex Therapeutics
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: pertuzumab;   Drug: trastuzumab;   Drug: Aromatase Inhibitor;   Drug: Induction Chemotherapy
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Smoldering Multiple Myeloma
Interventions:   Drug: Siltuximab;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified February 2012

Condition:   Prostate Cancer
Intervention:   Drug: Degarelix
Sponsors:   Ferring Pharmaceuticals;   Ferring Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component
Interventions:   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: Temozolomide;   Drug: KLH
Sponsors:   Celldex Therapeutics;   Celldex Therapeutics
Recruiting - verified May 2012

Condition:   Pancreatic Cancer
Interventions:   Drug: GS-6624;   Drug: GS-6624;   Drug: Placebo;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: Gemcitabine;   Drug: GS-6624
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Condition:   Colorectal Cancer
Interventions:   Drug: GS-6624;   Drug: FOLFIRI;   Drug: GS-6624;   Drug: FOLFIRI;   Drug: GS-6624;   Drug: FOLFIRI;   Drug: Placebo;   Drug: FOLFIRI
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Drug: paclitaxel;   Drug: pazopanib hydrochloride;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Colorectal Cancer, Metastatic
Interventions:   Other: Pharmacokinetic 5-FU dose adjustment using OnDose® assay;   Other: Standard of care
Sponsors:   Myriad Genetic Laboratories, Inc.;   Myriad Genetic Laboratories, Inc.
Recruiting - verified February 2012

Condition:   Lymphoma
Interventions:   Drug: alisertib;   Genetic: fluorescence in situ hybridization;   Genetic: microarray analysis;   Genetic: mutation analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Acute Lymphoid Leukemia;   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Multiple Myeloma;   Solid Tumors
Intervention:   Drug: brentuximab vedotin
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.
Recruiting - verified April 2012

Condition:   Leukemia, Pediatric
Intervention:   Drug: Dasatinib
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Children's Oncology Group;   EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012

Condition:   Non-Small Cell Lung Cancer
Intervention:  
Sponsors:   Precision Therapeutics;   Precision Therapeutics
Recruiting - verified January 2012

Condition:   Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions:   Drug: MEDI-551;   Drug: Rituximab;   Drug: ICE;   Drug: DHAP;   Procedure: Autologous Stem Cell Transplant (ASCT)
Sponsors:   MedImmune LLC;   MedImmune LLC
Recruiting - verified April 2012

Conditions:   Non-small Cell Lung Cancer (NSCLC);   Stage IV NSCLC;   Metastatic NSCLC
Interventions:   Drug: Cabazitaxel-XRP6258;   Drug: Cabazitaxel-XRP6258
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Sanofi-Aventis
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: fulvestrant;   Drug: GDC-0941;   Drug: GDC-0980;   Drug: placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Biological: Ramucirumab (IMC-1121B);   Drug: Eribulin
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified May 2012

Condition:   Metastatic Pancreatic Adenocarcinoma
Interventions:   Drug: Number 1 - Capecitabine and ruxolitinib;   Drug: Number 2 - Capecitabine and placebo
Sponsors:   Incyte Corporation;   Incyte Corporation
Recruiting - verified May 2012

Condition:   Endometrial Neoplasms
Interventions:   Drug: PF-04691502;   Drug: PF-05212384;   Drug: PF-04691502;   Drug: PF-05212384
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Conditions:   Cervical Cancer;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Sexuality and Reproductive Issues
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Lymphoma, B-Cell;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
Intervention:   Drug: brentuximab vedotin
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.
Recruiting - verified April 2012

Conditions:   Prostatic Neoplasm;   Prostate Cancer;   Prostatic Adenocarcinoma
Interventions:   Biological: sipuleucel-T;   Drug: leuprolide acetate
Sponsors:   Dendreon;   Dendreon
Recruiting - verified May 2012

Condition:   Lymphoma, B-Cell
Interventions:   Drug: RO50722759;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2012

Condition:   Lymphocytic Leukemia, Chronic
Interventions:   Drug: RO5072759;   Drug: RO5072759
Sponsors:   Genentech;   Genentech
Recruiting - verified November 2011

Conditions:   Cognitive/Functional Effects;   Leukemia;   Neurotoxicity;   Pain;   Therapy-related Toxicity
Interventions:   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: hydrocortisone sodium succinate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: selective external radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Colorectal Neoplasms;   Digestive System Diseases;   Colonic Diseases;   Colorectal Cancer
Intervention:  
Sponsors:   Exact Sciences Corporation;   Exact Sciences Corporation
Recruiting - verified August 2011

Conditions:   Leukemia;   Lymphoma
Interventions:   Drug: dexamethasone;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: pegaspargase;   Drug: temsirolimus;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Hepato/Renal Fibrocystic Disease;   Autosomal Recessive Polycystic Kidney Disease;   Joubert Syndrome;   Bardet Biedl Syndrome;   Meckel-Gruber Syndrome;   Congenital Hepatic Fibrosis;   Caroli Syndrome;   Oro-Facial-Digital Syndrome Type I;   Nephronophithisis;   Glomerulocystic Kidney Disease
Intervention:  
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011

Condition:   Pancreatic Cancer
Intervention:   Drug: dasatinib
Sponsors:   Otsuka Pharmaceutical Development & Commercialization, Inc.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012

Condition:   Neuroblastoma
Interventions:   Drug: Zoledronic Acid;   Biological: Aldesleukin
Sponsors:   University of Alabama at Birmingham;   Joseph Pressey, MD
Recruiting - verified December 2011

Conditions:   Arthralgia;   Breast Cancer;   Pain
Interventions:   Dietary Supplement: omega-3 fatty acid;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Breast Neoplasms;   Peritoneal Neoplasms;   Ovarian Neoplasms;   Pancreatic Neoplasms;   Stomach Neoplasms
Interventions:   Other: ²¹²Pb-TCMC-Trastuzumab;   Biological: trastuzumab
Sponsors:   Areva Med LLC;   Areva Med LLC
Recruiting - verified January 2012

Conditions:   Metastatic ER+ Her2- Breast Cancer;   Postmenopausal
Interventions:   Drug: Exemestane;   Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane;   Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified May 2012

Condition:   Acute Myeloid Leukemia
Intervention:  
Sponsors:   Center for International Blood and Marrow Transplant Research;   Center for International Blood and Marrow Transplant Research;   Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT);   Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012

Conditions:   Recurrent Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Intervention:   Biological: Chimeric monoclonal antibody (TRC105) to CD105
Sponsors:   Tracon Pharmaceuticals Inc.;   Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012

Condition:   Colorectal Cancer
Interventions:   Drug: bevacizumab;   Drug: FOLFIRI regimen;   Drug: mFOLFOX6
Sponsors:   Genentech;   Genentech
Recruiting - verified December 2011

Condition:   Lambert Eaton Myasthenic Syndrome
Interventions:   Drug: Amifampridine Phosphate;   Drug: Placebo
Sponsors:   BioMarin Pharmaceutical;   BioMarin Pharmaceutical
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: bortezomib;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: paclitaxel;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: assessment of therapy complications;   Procedure: quality-of-life assessment
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group
Recruiting - verified May 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: bevacizumab;   Drug: carboplatin;   Drug: MEGF0444A;   Drug: paclitaxel;   Drug: placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Conditions:   Pain;   Advanced Cancer
Interventions:   Drug: Sativex®;   Drug: Placebo (GA-0034)
Sponsors:   GW Pharmaceuticals Ltd.;   GW Pharmaceuticals Ltd.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011

Conditions:   Muscle Wasting;   Non Small Cell Lung Cancer
Interventions:   Drug: GTx-024;   Drug: placebo
Sponsors:   GTx;   GTx;   Harrison Clinical Research
Recruiting - verified May 2012

Conditions:   Muscle Wasting;   Non-Small Cell Lung Cancer
Interventions:   Drug: GTx-024;   Drug: placebo
Sponsors:   GTx;   GTx;   Harrison Clinical Research
Recruiting - verified May 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: Standard of care treatment
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Hematological Malignancies;   Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders;   Hurler Syndrome (MPS I);   Krabbe Disease (Globoid Leukodystrophy);   X-linked Adrenoleukodystrophy;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention:   Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors:   Center for International Blood and Marrow Transplant Research;   Center for International Blood and Marrow Transplant Research;   National Marrow Donor Program
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: accelerated radiation therapy;   Radiation: hypofractionated radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: whole breast irradiation
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   B Cell Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Intervention:   Drug: AVL-292
Sponsors:   Avila Therapeutics;   Avila Therapeutics;   The Leukemia and Lymphoma Society
Recruiting - verified May 2011

Condition:   Colon Cancer and Rectal Cancer
Interventions:   Drug: FOLFIRI;   Drug: E7820
Sponsors:   Eisai Inc.;   Eisai Inc.;   PharmaBio Development Inc.
Recruiting - verified May 2012

Conditions:   DDD;   Deformity;   Tumor;   Fracture
Intervention:  
Sponsors:   Biomet, Inc.;   Biomet, Inc.
Recruiting - verified February 2012

Condition:   Non-Small Cell Lung Cancer (NSCLC)
Interventions:   Drug: Dacomitinib (PF-00299804);   Drug: Active Comparator (erlotinib)
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Conditions:   Pain;   Advanced Cancer
Intervention:   Drug: Sativex®
Sponsors:   GW Pharmaceuticals Ltd.;   GW Pharmaceuticals Ltd.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified April 2011

Condition:   Chemotherapy-Induced Nausea and Vomiting
Interventions:   Drug: Netupitant and Palonosetron;   Drug: Palonosetron
Sponsors:   Helsinn Healthcare SA;   Helsinn Healthcare SA;   Parexel
Recruiting - verified December 2011

Condition:   Hepatocellular Carcinoma
Interventions:   Device: HepaSphere/QuadraSphere Microspheres;   Procedure: PVA, lipiodol, doxorubicin
Sponsors:   Merit Medical Systems, Inc.;   Merit Medical Systems, Inc.
Recruiting - verified January 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63);   Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified October 2011

Condition:   Adult Solid Tumor
Intervention:   Drug: TRC105 and Bevacizumab
Sponsors:   Tracon Pharmaceuticals Inc.;   Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012

Condition:   Metastatic Breast Cancer
Intervention:   Drug: TRC105
Sponsors:   Tracon Pharmaceuticals Inc.;   Tracon Pharmaceuticals Inc.;   Roswell Park Cancer Institute;   Department of Defense
Recruiting - verified March 2012

Condition:   Prostate Cancer
Interventions:   Dietary Supplement: Vitamin D and Genistein;   Other: Placebo
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison;   University of Alabama at Birmingham;   University of Rochester;   University of Minnesota - Clinical and Translational Science Institute;   Lahey Clinic;   Urology San Antonio
Recruiting - verified January 2012

Condition:   Basal Cell Carcinoma
Intervention:   Drug: LDE225
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Diffuse Large B-cell Lymphoma;   de Novo DLBCL;   DLBCL Transformed From Indolent Lymphoma;   Follicular Grade 3 Lymphoma
Interventions:   Drug: Pixantrone + Rituximab;   Drug: Gemcitabine + Rituximab
Sponsors:   Cell Therapeutics;   Cell Therapeutics
Recruiting - verified May 2012

Conditions:   Prostate Cancer;   Prostatic Neoplasm
Intervention:   Drug: abiraterone acetate in combination with prednisone
Sponsors:   Janssen Biotech, Inc.;   Janssen Biotech, Inc.
Recruiting - verified May 2012

Conditions:   Head and Neck Cancer;   Advanced Solid Tumors
Intervention:   Genetic: Ad/PNP and fludarabine monophosphate
Sponsors:   PNP Therapeutics, Inc.;   PNP Therapeutics, Inc.
Recruiting - verified December 2011

Condition:   Prostate Cancer
Interventions:   Drug: Cabazitaxel (XRP6258);   Drug: Docetaxel (XRP6976);   Drug: Prednisone
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified April 2012

Condition:   Prostate Cancer
Interventions:   Drug: Cabazitaxel (XRP6258);   Drug: Prednisone
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis
Recruiting - verified May 2012

Conditions:   Advanced Prostate Cancer;   Prostatic Neoplasms
Intervention:   Biological: sipuleucel-T
Sponsors:   Dendreon;   Dendreon
Recruiting - verified March 2012

Condition:   Stage IV Non-small Cell Lung Cancer
Intervention:   Drug: Belionstat, Carboplatin, Paclitaxel
Sponsors:   Spectrum Pharmaceuticals, Inc;   Spectrum Pharmaceuticals, Inc;   TopoTarget A/S
Recruiting - verified May 2012

Conditions:   Fungal Infection;   Leukemia;   Neutropenia
Interventions:   Drug: caspofungin acetate;   Drug: fluconazole
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: Sapacitabine and decitabine;   Drug: Decitabine
Sponsors:   Cyclacel Pharmaceuticals, Inc.;   Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011

Condition:   Colorectal Cancer
Interventions:   Biological: Imprime PGG + cetuximab;   Drug: Cetuximab
Sponsors:   Biothera;   Biothera
Recruiting - verified April 2012

Condition:   Renal Cell Carcinoma
Intervention:   Drug: Tivozanib
Sponsors:   AVEO Pharmaceuticals, Inc.;   AVEO Pharmaceuticals, Inc.
Recruiting - verified September 2011

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: bendamustine;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: RO5072759
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Condition:   Prostatic Neoplasms
Interventions:   Drug: MDV3100;   Drug: Bicalutamide
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc;   Medivation, Inc.
Recruiting - verified March 2012

Conditions:   Cognitive/Functional Effects;   Colorectal Cancer;   Neurotoxicity
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified February 2012

Conditions:   Indolent Non-Hodgkin Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Lymphoplasmacytoid Lymphoma;   Marginal Zone Lymphoma
Intervention:   Drug: CAL-101
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Glioblastoma Multiforme
Interventions:   Biological: ICT-107;   Biological: Placebo DC
Sponsors:   ImmunoCellular Therapeutics, Ltd.;   ImmunoCellular Therapeutics, Ltd.
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: imetelstat sodium;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Drug: systemic chemotherapy;   Drug: tamoxifen citrate
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Solid Organ Tumors
Intervention:  
Sponsors:   Precision Therapeutics;   Precision Therapeutics
Recruiting - verified January 2012

Condition:   Melanoma (Skin)
Interventions:   Biological: ipilimumab;   Biological: recombinant interferon alfa-2b
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Cervical Cancer
Interventions:   Biological: live-attenuated Listeria monocytogenes cancer vaccine ADXS11-001;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Dysphagia;   Lung Cancer;   Pain
Interventions:   Drug: Manuka honey;   Drug: chemotherapy;   Other: questionnaire administration;   Procedure: adjuvant therapy;   Procedure: assessment of therapy complications;   Procedure: quality-of-life assessment;   Procedure: standard follow-up care;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer;   Gastric Cancer
Intervention:   Drug: Akt inhibitor MK2206
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Pain
Interventions:   Drug: Sativex®;   Drug: Placebo (GA-0034)
Sponsors:   GW Pharmaceuticals Ltd.;   GW Pharmaceuticals Ltd.;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011

Conditions:   Colorectal Neoplasms;   Digestive System Diseases;   Colonic Diseases;   Colorectal Cancer
Intervention:  
Sponsors:   Exact Sciences Corporation;   Exact Sciences Corporation
Recruiting - verified August 2011

Conditions:   Incurable Metastatic Colorectal Carcinoma;   Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: PX-866 and cetuximab;   Drug: Cetuximab;   Drug: PX-866 and cetuximab;   Drug: Cetuximab
Sponsors:   Oncothyreon Inc.;   Oncothyreon Inc.
Recruiting - verified April 2012

Condition:   Metastatic Breast Cancer
Interventions:   Drug: BKM120;   Drug: BEZ235;   Drug: Letrozole;   Drug: BKM120
Sponsors:   Vanderbilt-Ingram Cancer Center;   Vanderbilt-Ingram Cancer Center
Recruiting - verified July 2011

Condition:   Brain Metastases
Intervention:  
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Recruiting - verified July 2011

Condition:   Breast Cancer
Interventions:   Procedure: palliative surgery;   Procedure: therapeutic conventional surgery;   Radiation: palliative radiation therapy;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Hepatocellular Carcinoma (HCC)
Interventions:   Procedure: Transcatheter arterial chemoembolization;   Procedure: Stereotactic Body Radiation Therapy
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Recruiting - verified July 2011

Condition:   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: wild-type reovirus;   Drug: cyclophosphamide;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Chronic Myeloid Leukemia
Intervention:  
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   ICON Clinical Research
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone (Oral);   Drug: Dexamethasone (IV);   Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified May 2012

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: ISIS EIF4E Rx;   Drug: ISIS EIF4E Rx;   Drug: ISIS EIF4E Rx;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Isis Pharmaceuticals;   Isis Pharmaceuticals
Recruiting - verified March 2012

Conditions:   Brain and Central Nervous System Tumors;   Kidney Cancer;   Sarcoma
Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Small Intestine Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Islet Cell Tumor;   Pancreatic Cancer
Interventions:   Biological: bevacizumab;   Drug: everolimus;   Drug: octreotide acetate
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer;   Periampullary Adenocarcinoma
Interventions:   Drug: AZD2171;   Drug: mFOLFOX6
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Cognitive/Functional Effects;   Metastatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: quality-of-life assessment;   Radiation: intensity-modulated radiation therapy;   Radiation: whole-brain radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: BMS-754807;   Drug: letrozole
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Mayo Clinic
Recruiting - verified December 2011

Conditions:   Prostate Neoplasms;   Genital Neoplasms, Male;   Urogenital Neoplasms;   Genital Diseases, Male
Intervention:   Drug: Abiraterone Acetate
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: irinotecan hydrochloride;   Drug: temozolomide
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: temsirolimus;   Drug: vinorelbine tartrate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: MDV3100;   Drug: Placebo
Sponsors:   Medivation, Inc.;   Medivation, Inc.;   Astellas Pharma Inc
Recruiting - verified February 2012

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Dovitinib;   Drug: Sorafenib
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Non Small Cell Lung Cancer (NSCLC);   Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions:   Drug: Docetaxel;   Drug: PX-866 and Docetaxel
Sponsors:   Oncothyreon Inc.;   Oncothyreon Inc.
Recruiting - verified March 2012

Condition:   Mesothelioma
Intervention:   Drug: Zometa (zoledronic acid)
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Novartis Pharmaceuticals
Recruiting - verified November 2011

Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions:   Biological: trastuzumab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Custirsen Sodium, Docetaxel, Prednisone;   Drug: Docetaxel, Prednisone
Sponsors:   Teva Pharmaceutical Industries;   Teva Pharmaceutical Industries;   OncoGenex Technologies
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Obstructive Jaundice;   Pancreatic Cancer
Interventions:   Procedure: Metal stent placement in the bile duct;   Procedure: Plastic stent
Sponsors:   University of Alabama at Birmingham;   Shyam Varadarajulu;   University of Virginia
Recruiting - verified October 2011

Condition:   Chronic Lymphocytic Leukemia (CLL)
Interventions:   Other: TRU-016 and bendamustine;   Other: TRU-016 and bendamustine;   Drug: Bendamustine
Sponsors:   Emergent Product Development Seattle LLC;   Emergent Product Development Seattle LLC
Recruiting - verified February 2012

Conditions:   Estrogen Receptor Negative (ER-Negative) Breast Cancer;   Progesterone Receptor Negative (PR-Negative) Breast Cancer;   Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer;   Brain Metastases
Intervention:   Drug: INIPARIB + irinotecan
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   UNC Lineberger Comprehensive Cancer Center
Recruiting - verified October 2011

Condition:   Neuroblastoma
Interventions:   Drug: busulfan;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: isotretinoin;   Drug: melphalan;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: iobenguane I 131
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: ruxolitinib phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Kidney Cancer
Interventions:   Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Soft Tissue Sarcoma
Interventions:   Drug: doxorubicin in combination with palifosfamide-tris;   Drug: doxorubicin in combination with placebo
Sponsors:   ZIOPHARM;   ZIOPHARM
Recruiting - verified April 2012

Condition:   Carcinoma, Squamous Cell of the Head and Neck
Interventions:   Biological: REOLYSIN;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
Sponsors:   Oncolytics Biotech;   Oncolytics Biotech
Recruiting - verified March 2012

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Kidney Cancer;   Leukemia;   Liver Cancer;   Neuroblastoma;   Sarcoma
Interventions:   Drug: alisertib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Her2 Negative Breast Cancer Patients
Interventions:   Drug: MM-121 (SAR256212) and Exemestane;   Drug: Placebo and Exemestane
Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals
Recruiting - verified May 2012

Conditions:   Breast Cancer;   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Other: questionnaire administration;   Procedure: evaluation of cancer risk factors;   Procedure: quality-of-life assessment;   Procedure: study of high risk factors
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: cytology specimen collection procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Hepatocellular Carcinoma
Interventions:   Biological: Placebo;   Biological: Ramucirumab DP (IMC-1121B)
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified February 2012

Condition:   Unresectable Stage III or Stage IV Melanoma
Interventions:   Drug: E7080;   Drug: E7080
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified January 2012

Condition:   Breast Cancer
Interventions:   Drug: tamoxifen citrate;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: gamma-secretase inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Neoplasms
Interventions:   Drug: BIBW 2992;   Drug: trastuzumab;   Drug: vinorelbine;   Drug: vinorelbine
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Kidney Cancer
Interventions:   Drug: everolimus;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Metastatic Breast Cancer;   Trastuzumab;   BKM120;   HER2+
Intervention:   Drug: BKM120
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Cancer
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National Cancer Institute (NCI);   Fred Hutchinson Cancer Research Center;   Nationwide Children's Hospital;   M.D. Anderson Cancer Center;   University of Southern California;   Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: EGEN-001;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Acute Myelogenous Leukemia;   Diffuse Large B-Cell Leukemia;   Chronic Lymphocytic Leukemia;   Follicular Lymphoma
Interventions:   Drug: BMS-936564 (Anti-CXCR4);   Drug: BMS-936564 (Anti-CXCR4)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified December 2011

Conditions:   Breast Cancer;   Overweight;   Obesity
Interventions:   Behavioral: Intensive Group;   Behavioral: Less Intensive Group
Sponsors:   University of California, San Diego;   University of California, San Diego;   Washington University School of Medicine;   University of Colorado, Denver;   University of Alabama at Birmingham
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: pemetrexed disodium
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Peripheral T-cell Lymphoma
Intervention:  
Sponsors:   Allos Therapeutics;   Allos Therapeutics
Recruiting - verified December 2011

Conditions:   brca1 Mutation Carrier;   brca2 Mutation Carrier;   Breast Cancer
Interventions:   Dietary Supplement: cholecalciferol;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Stages II-III Breast Cancer
Interventions:   Drug: Nanoparticle Albumin Bound Paclitaxel;   Drug: doxorubicin;   Drug: cyclophosphamide
Sponsors:   University of South Alabama;   University of South Alabama;   Celgene Corporation
Recruiting - verified August 2011

Conditions:   Chronic Lymphocytic Leukemia;   Lymphoma, Non-Hodgkin;   Acute Myeloid Leukemia;   Multiple Myeloma
Intervention:   Drug: CAL-101
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified January 2012

Conditions:   Head and Neck Cancer;   Precancerous Condition
Interventions:   Biological: cetuximab;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Condition:   Squamous Cell Lung Cancer
Interventions:   Drug: gemcitabine/carboplatin;   Drug: gemcitabine/carboplatin plus Iniparib
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   BiPar Sciences
Recruiting - verified March 2012

Condition:   Liver Cancer
Interventions:   Drug: iodinated contrast dye;   Drug: motexafin gadolinium;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   American College of Radiology Imaging Network;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: carboplatin;   Drug: oxaliplatin;   Drug: paclitaxel;   Procedure: quality-of-life assessment
Sponsors:   University College, London;   University College, London;   National Cancer Institute (NCI);   Gynecologic Oncology Group
Recruiting - verified December 2011

Condition:   Colorectal Cancer
Interventions:   Biological: cetuximab;   Biological: ramucirumab;   Drug: irinotecan hydrochloride
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Indolent Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma
Interventions:   Drug: CAL-101;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Fludarabine;   Drug: Everolimus;   Drug: Bortezomib;   Drug: Chlorambucil
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Intervention:  
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified June 2011

Condition:   Pancreatic Cancer
Interventions:   Biological: HyperAcute-Pancreas Immunotherapy;   Drug: Gemcitabine;   Radiation: 5FU Chemoradiation
Sponsors:   NewLink Genetics Corporation;   NewLink Genetics Corporation
Recruiting - verified May 2012

Conditions:   Chronic Myeloid Leukemia;   Acute Lymphoblastic Leukemia
Intervention:   Drug: Nilotinib
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: Placebo;   Drug: Denosumab
Sponsors:   Amgen;   Amgen;   Daiichi Sankyo Inc.
Recruiting - verified May 2012

Condition:   Non-Hodgkin's Lymphoma
Interventions:   Drug: bendamustine;   Drug: RO5072759
Sponsors:   Genentech;   Genentech;   Roche Pharma AG
Recruiting - verified May 2012

Condition:   Tumor
Interventions:   Drug: Sunitinib;   Procedure: Surgery
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Pfizer
Recruiting - verified September 2011

Condition:   Sarcoma
Interventions:   Biological: cixutumumab;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: irinotecan hydrochloride;   Drug: temozolomide;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: celecoxib;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors
Interventions:   Drug: Neratinib;   Drug: ABT-888;   Drug: Standard Therapy;   Drug: AMG 386;   Drug: AMG 479 (Ganitumab) plus Metformin
Sponsors:   Foundation for the National Institutes of Health;   Foundation for the National Institutes of Health
Recruiting - verified December 2011

Conditions:   Functional Disability;   Dementia;   Heart Disease;   Stroke;   Cancer;   Bleeding
Interventions:   Drug: 100 mg enteric-coated aspirin;   Drug: Placebo
Sponsors:   Minneapolis Medical Research Foundation;   Minneapolis Medical Research Foundation;   National Health and Medical Research Council, Australia;   Bayer;   Monash University;   Berman Center for Outcomes and Clinical Research
Recruiting - verified July 2011

Condition:   Recurrent or Refractory Pediatric Ependymoma
Interventions:   Drug: erlotinib;   Drug: etoposide
Sponsors:   OSI Pharmaceuticals;   OSI Pharmaceuticals;   Astellas Pharma Global Development, Inc.
Recruiting - verified February 2012

Condition:   Liver Cancer
Interventions:   Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   Basal Cell Carcinoma;   Squamous Cell Carcinoma
Intervention:   Radiation: electronic brachytherapy
Sponsors:   Xoft, Inc.;   Xoft, Inc.
Recruiting - verified March 2012

Conditions:   Colorectal Cancer;   Precancerous Condition
Interventions:   Drug: rosuvastatin;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Hepatocellular Carcinoma;   Liver Cancer
Interventions:   Drug: Sorafenib;   Radiation: Stereotactic Body Radiotherapy (SBRT)
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified April 2012

Condition:   Refractory Cutaneous T-cell Lymphoma
Interventions:   Drug: bexarotene;   Drug: bexarotene
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified January 2012

Conditions:   Lymphoma;   Lymphoproliferative Disorder
Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   HPV16+;   Cervical Intraepithelial Neoplasia (CIN 2/3)
Interventions:   Biological: DNA vaccination;   Device: Gene gun vaccine;   Biological: intramuscular vaccination;   Biological: intra-lesional vaccine administration;   Procedure: therapeutic resection of the lesion
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   B-cell Malignancies
Intervention:   Drug: MEDI-551
Sponsors:   MedImmune LLC;   MedImmune LLC
Recruiting - verified May 2012

Condition:   Liver Cancer
Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: liver transplantation;   Procedure: therapeutic conventional surgery
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cediranib maleate;   Drug: cilengitide;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Procedure: magnetic resonance imaging
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Neurotoxicity
Interventions:   Drug: temozolomide;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-Hodgkin's Lymphoma
Interventions:   Drug: YM155;   Biological: Rituximab
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc
Recruiting - verified March 2012

Condition:   Carcinoma, Non-Small-Cell Lung
Intervention:  
Sponsors:   Medical Prognosis Institute A/S;   Medical Prognosis Institute A/S
Recruiting - verified June 2011

Condition:   Non-Small Cell Lung Cancer (NSCLC)
Intervention:   Drug: PF-00299804
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Mental Health (NIMH)
Recruiting - verified June 2011

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;   Drug: Placebo in combination with cisplatin and docetaxel or paclitaxel
Sponsors:   BioNumerik Pharmaceuticals, Inc.;   BioNumerik Pharmaceuticals, Inc.
Recruiting - verified January 2011

Condition:   Head and Neck Cancer
Interventions:   Biological: cetuximab;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Ovarian Cancer;   Sarcoma
Interventions:   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Malignant Neoplasm Overlapping Lip Site;   Mouth Neoplasms;   Malignant Neoplasm of Other and Ill-defined Sites in the Lip, Oral Cavity and Pharynx;   Leukoplakia;   Other Lesions of Oral Mucosa;   Pigmented Oral Mucosal Lesion;   Unspecified Lesions of Oral Mucosa;   Oral Lichenoid Lesions;   Premalignant Lesion;   Other and Unspecified Lesions of Oral Mucosa;   Granuloma and Granuloma-like Lesions of Oral Mucosa;   Diseases of the Oral Soft Tissue, Excluding Lesions Specific for Gingiva and Tongue;   Oral Premalignant Lesion;   Oral Premalignant Neoplasms;   Oral Leukoplakia
Interventions:   Drug: Pioglitazone;   Drug: Placebo
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   University of Minnesota - Clinical and Translational Science Institute;   Memorial Sloan-Kettering Cancer Center;   University of Wisconsin, Madison;   University of Alabama at Birmingham;   University of Iowa;   University of Maryland;   Roswell Park Cancer Institute;   Columbia University;   Weill Medical College of Cornell University;   European Institute of Oncology
Recruiting - verified April 2012

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention:   Drug: SGN-35
Sponsors:   Seattle Genetics, Inc.;   Seattle Genetics, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012

Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Endometrial Cancer
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Breast Cancer
Intervention:  
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   University of Chicago;   Dana-Farber Cancer Institute;   Georgetown University;   Johns Hopkins University;   M.D. Anderson Cancer Center;   University of Alabama at Birmingham;   University of California, San Francisco;   University of North Carolina;   Duke University;   Vanderbilt-Ingram Cancer Center;   Indiana University Melvin and Bren Simon Cancer Center;   Mayo Clinic;   University of Pittsburgh;   University of Michigan Health System
Recruiting - verified March 2012

Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: crizotinib;   Other: pharmacogenomic studies;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Colon Cancer With Metastases to the Liver
Interventions:   Device: LC bead loaded with Irinotecan;   Drug: FOLFOX6 and Avastin
Sponsors:   University of Louisville;   University of Louisville;   Biocompatibles UK Ltd
Recruiting - verified November 2011

Condition:   Carcinoma, Non-Small-Cell Lung
Intervention:   Drug: PF-02341066
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Conditions:   Pain, Burning;   Pain, Crushing;   Pain, Migratory;   Pain, Radiating;   Pain, Splitting
Interventions:   Drug: JNJ-42160443;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC
Recruiting - verified May 2012

Conditions:   Metastatic Cancer;   Pain
Interventions:   Radiation: external beam radiation therapy;   Radiation: image-guided radiation therapy;   Radiation: radiosurgery;   Radiation: stereotactic body radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Leukemia-relapsed or Refractory;   Cancer
Interventions:   Drug: GSK1120212;   Drug: GSK1120212
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified April 2012

Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Biological: IMC-3G3;   Drug: Paclitaxel;   Drug: carboplatin
Sponsors:   ImClone LLC;   ImClone LLC
Recruiting - verified February 2012

Condition:   Head and Neck Squamous Cell Carcinoma
Intervention:   Drug: Lymphoseek
Sponsors:   Navidea Biopharmaceuticals;   Navidea Biopharmaceuticals
Recruiting - verified March 2012

Conditions:   Cancer;   Colon Cancer;   Colorectal Cancer;   Fever;   Locally Advanced;   Metastatic Colorectal Cancer;   Neutropenia;   Rectal Cancer
Interventions:   Drug: Pegfilgrastim;   Drug: Placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified January 2012

Condition:   Neuroblastoma
Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: nucleic acid amplification;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: cytology specimen collection procedure;   Other: flow cytometry;   Procedure: biopsy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Cancer
Interventions:   Genetic: DNA analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: cytology specimen collection procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: anti-PDGFR alpha monoclonal antibody IMC-3G3;   Biological: ramucirumab
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI);   ImClone LLC
Recruiting - verified April 2012

Condition:   Sarcoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Endometrial Cancer
Interventions:   Drug: Ixabepilone;   Drug: Doxorubicin;   Drug: Paclitaxel
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Drug: Everolimus;   Drug: Placebo
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Procedure: assessment of therapy complications
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Ipilimumab;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified December 2011

Condition:   Leukemia
Interventions:   Drug: arsenic trioxide;   Drug: cytarabine;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: tretinoin;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Non-Small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified May 2012

Conditions:   Small Cell Lung Cancer;   Extensive Stage;   Chemonaive
Intervention:   Drug: Bendamustine, Irinotecan, Etoposide/Carboplatin
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   National Comprehensive Cancer Network
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Biological: pegfilgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Neurofibromatosis Type 1
Interventions:   Drug: Lovastatin ™;   Device: placebo
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Children's Hospital Boston;   Children's Hospital Philadelphia;   Children's Research Institute;   Children's Hospital Medical Center, Cincinnati;   National Cancer Institute (NCI);   University of Chicago;   University of Utah;   Washington University School of Medicine;   The Children's Hospital at Westmead
Recruiting - verified July 2011

Conditions:   Psoriasis;   Melanoma;   Non-melanoma Skin Cancer
Intervention:   Drug: etanercept
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Amgen
Recruiting - verified August 2011

Conditions:   Endometrial Cancer;   Fatigue;   Neurotoxicity
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Cervical Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: paclitaxel;   Drug: topotecan hydrochloride
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
Interventions:   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Brain and Central Nervous System Tumors;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Therapy-related Toxicity
Interventions:   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Biological: Bevacizumab
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Conditions:   Advanced or Metastatic Solid Tumors;   Advanced or Metastatic Breast Cancer
Interventions:   Drug: Azacitidine (Vidaza);   Drug: Nab-paclitaxel (Abraxane)
Sponsors:   University of South Alabama;   University of South Alabama;   Celgene Corporation
Recruiting - verified August 2011

Condition:   Lung Cancer
Intervention:   Device: Biomarker (not used as an intervention)
Sponsors:   Allegro Diagnostics, Corp.;   Allegro Diagnostics, Corp.;   University of Pennsylvania;   Columbia University;   Temple University;   Indiana University;   University of Alabama at Birmingham;   University of Missouri-Columbia;   Louisiana State University Health Sciences Center in New Orleans;   University of Wisconsin, Madison;   Medical University of South Carolina;   National Jewish Health;   Overlake Hospital Bellevue WA;   Pulmonary and Allergy Associates of New Jersey;   Pulmonary Associates of Arizona;   William Jennings Bryan Dorn VA Medical Center;   Virginia Commonwealth University;   Jamaica Hospital Medical Center;   North Florida/South Georgia Veterans Health System;   Steward St. Elizabeth;   University of California, Davis;   Yale University Medical Center;   The Cleveland Clinic;   Johns Hopkins University
Recruiting - verified May 2012

Condition:   Osteosarcoma
Interventions:   Drug: Saracatinib;   Drug: Placebo
Sponsors:   Sarcoma Alliance for Research through Collaboration;   Sarcoma Alliance for Research through Collaboration;   AstraZeneca
Recruiting - verified March 2012

Condition:   Pancreatic Cancer
Interventions:   Drug: Kanglaite Injection plus gemcitabine;   Drug: Gemcitabine
Sponsors:   KangLaiTe USA;   KangLaiTe USA
Recruiting - verified January 2012

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Liver Cancer;   Neuroblastoma;   Ototoxicity;   Ovarian Cancer;   Sarcoma
Interventions:   Drug: sodium thiosulfate;   Procedure: examination
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Ovarian Cancer
Intervention:  
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Recruiting - verified July 2011

Condition:   Colorectal Cancer
Interventions:   Biological: cetuximab;   Drug: capecitabine;   Drug: oxaliplatin;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Procedure: neoadjuvant therapy;   Procedure: therapeutic surgical procedure;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Vinorelbine;   Drug: Paclitaxel;   Drug: Carboplatin;   Radiation: Thoracic Radiation Therapy (TRT);   Radiation: Thoracic Radiation Therapy (TRT)
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Glioblastoma
Intervention:   Drug: bsi-201 plus temozolomide
Sponsors:   Sanofi-Aventis;   Sanofi-Aventis;   BiPar Sciences
Recruiting - verified June 2011

Conditions:   Lung Neoplasm;   Carcinoma Non-small Cell Lung Cancer Stage IIIA;   Carcinoma Non-small Cell Lung Cancer Stage IIIB;   Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions:   Biological: Lucanix™;   Other: Placebo Comparator
Sponsors:   NovaRx Corporation;   NovaRx Corporation
Recruiting - verified April 2012

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer;   Uterine Neoplasms;   Endometrial Cancer;   Vaginal Cancer;   Vulvar Cancer;   Cervical Cancer;   Lung Cancer;   Carcinoid Tumor of Lung;   Sarcoma of Lung;   Mesothelioma;   Colorectal Cancer
Intervention:  
Sponsors:   Precision Therapeutics;   Precision Therapeutics
Recruiting - verified June 2011

Condition:   Esophageal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: paclitaxel;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Paclitaxel;   Drug: Gemcitabine;   Biological: Avastin
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Genentech
Recruiting - verified August 2011

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: etoposide phosphate;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Lung Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
Recruiting - verified May 2012

Condition:   Chronic Lymphocytic Lymphoma
Intervention:   Biological: milatuzumab
Sponsors:   Immunomedics, Inc.;   Immunomedics, Inc.
Recruiting - verified February 2012

Condition:   Head and Neck Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Pancreatic Cancer
Intervention:  
Sponsors:   University of Alabama at Birmingham;   Charles Mel Wilcox, MD;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: sapacitabine;   Drug: sapacitabine;   Drug: sapacitabine;   Drug: sapacitabine;   Drug: sapacitabine;   Drug: sapacitabine;   Drug: sapacitabine;   Drug: Sapacitabine;   Drug: sapacitabine
Sponsors:   Cyclacel Pharmaceuticals, Inc.;   Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011

Conditions:   Neoplasm;   Arteriovenous Malformations
Intervention:   Radiation: Radiosurgery
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Health Services Foundation;   The Kirklin Clinic at Acton Road
Recruiting - verified July 2011

Condition:   Neuroendocrine Carcinoma
Interventions:   Biological: bevacizumab;   Biological: recombinant interferon alfa-2b;   Drug: octreotide acetate
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Recurrent Respiratory Papillomatosis
Interventions:   Drug: celebrex (celecoxib);   Drug: placebo capsules
Sponsors:   North Shore Long Island Jewish Health System;   North Shore Long Island Jewish Health System;   National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified January 2012

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: lestaurtinib;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Retinoblastoma
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: thiotepa;   Drug: vincristine sulfate;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain Tumors
Intervention:   Drug: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
Sponsors:   New York University School of Medicine;   New York University School of Medicine;   Children's Hospitals and Clinics of Minnesota;   Schneider Children's Hospital
Recruiting - verified January 2012

Condition:   Trismus
Interventions:   Device: Dynasplint Trismus System;   Other: Tongue Blades
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Dynasplint Systems, Inc.
Recruiting - verified December 2011

Condition:   Lung Cancer
Interventions:   Procedure: therapeutic thoracoscopy;   Procedure: videothoracoscopy
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   American College of Surgeons;   Southwest Oncology Group
Recruiting - verified April 2012

Conditions:   Non-Small Cell Lung Cancer;   Venous Thromboembolism
Intervention:   Drug: Carboplatin, Paclitaxel, Arixtra
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Recruiting - verified July 2011

Conditions:   Ototoxicity;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Procedure: management of therapy complications
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Bladder Cancer
Interventions:   Drug: gemcitabine hydrochloride;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Unruptured Brain Arteriovenous Malformation
Intervention:   Procedure: invasive therapy [endovascular procedures, neurosurgery, or radiotherapy, alone or in combination]
Sponsors:   Columbia University;   Columbia University;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified September 2011

Condition:   Thymoma
Interventions:   Drug: cisplatin and etoposide;   Procedure: Surgical Resection;   Radiation: Concurrent Radiotherapy
Sponsors:   Valley Health System;   Valley Health System
Recruiting - verified August 2011

Conditions:   Kidney Cancer;   Metastatic Cancer
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Breast Cancer;   Cognitive/Functional Effects;   Lung Cancer;   Metastatic Cancer;   Prostate Cancer
Interventions:   Radiation: radiation therapy;   Radiation: stereotactic radiosurgery
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   American College of Surgeons;   Eastern Cooperative Oncology Group;   Radiation Therapy Oncology Group
Recruiting - verified July 2011

Condition:   Neoplasms, Breast
Intervention:   Drug: lapatinib + capecitabine
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified April 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Drug: vinorelbine tartrate
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group
Recruiting - verified February 2012

Condition:   Prostate Cancer
Interventions:   Drug: antiandrogen therapy;   Drug: docetaxel
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011

Conditions:   Neurofibromatosis Type 1;   Sarcoma
Interventions:   Biological: filgrastim;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Sarcoma Alliance for Research through Collaboration;   Sarcoma Alliance for Research through Collaboration;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Adrenocortical Carcinoma
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: mitotane;   Procedure: conventional surgery
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Prostate Cancer
Interventions:   Drug: Docetaxel;   Drug: Prednisone
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs;   Sanofi-Aventis
Recruiting - verified September 2011

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified June 2011

Condition:   Breast Cancer
Interventions:   Radiation: 3-dimensional conformal accelerated partial breast irradiation;   Radiation: brachytherapy;   Radiation: whole breast irradiation
Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   Southwest Oncology Group
Recruiting - verified May 2012

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer - EORTC;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified December 2011